sincalide and Bulimia

sincalide has been researched along with Bulimia* in 5 studies

Trials

1 trial(s) available for sincalide and Bulimia

ArticleYear
Naloxone but not CCK-8 may attenuate binge-eating behavior in patients with the bulimia syndrome.
    Biological psychiatry, 1986, Volume: 21, Issue:14

    We undertook a study to see if putative anorectic agents could attenuate binge eating episodes in bulimic patients. Bolus intravenous administration, followed by continuous intravenous infusion of naloxone, resulted in a significant decrease in the amount of food consumed during binge-eating episodes, whereas bolus followed by continuous intravenous infusion of CCK-8 failed to significantly suppress binge eating behavior. These results suggest that the endogenous opioid system is involved in the maintenance of binge eating behavior in patients with bulimia.

    Topics: Adult; Appetite Depressants; Bulimia; Clinical Trials as Topic; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Naloxone; Sincalide

1986

Other Studies

4 other study(ies) available for sincalide and Bulimia

ArticleYear
Immunoendocrine aspects of anorexia nervosa.
    Psychiatry research, 1996, Apr-16, Volume: 62, Issue:1

    The T-lymphocyte proliferative response to phytohemoagglutinin (PHA) stimulation was the same in 11 anorexic women, 6 restricted (AN-R) and 5 bulimic (AN-B), and in 11 sex- and age-matched controls, in basal conditions and after acute administration of corticotropin-releasing hormone (CRH). Basal plasma levels of ACTH and cortisol were higher in patients than in controls, while beta-endorphin (beta-EP), growth hormone (GH) and prolactin (PRL) concentrations did not differ in the two groups. ACTH and beta-EP responses to CRH stimulation were blunted in patients, while those of cortisol did not differ in the two groups. ACTH, beta-EP and cortisol responses to the dexamethasone suppression test were impaired in 55% of the patients. Baseline T-lymphocyte concentrations of cholecystokinin-8 (CCK-8) and beta-EP were measured in another group of 56 anorexics, 33 restricted and 23 bulimic, and in 24 controls. CCK-8 values were significantly lower and beta-EP values significantly higher in patients than in controls.

    Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anorexia Nervosa; beta-Endorphin; Bulimia; Corticotropin-Releasing Hormone; Female; Humans; Hydrocortisone; Immune Tolerance; Lymphocyte Activation; Prolactin; Sincalide; T-Lymphocytes

1996
T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa.
    Psychiatry research, 1995, Nov-29, Volume: 59, Issue:1-2

    Concentrations of cholecystokinin-8 (CCK-8) and beta-endorphin (beta-EP) in T-lymphocytes of 26 women with bulimia nervosa (BN) and in 26 age- and sex-matched healthy comparison subjects were measured. Ten patients were then treated with 300 mg/day of fluvoxamine, p.o., and five patients were treated with 300 mg/day of amineptine, p.o., for 4 months. Concentrations of the two peptides were measured again after 1, 2, and 4 months of therapy. Basal CCK-8 values were significantly lower in patients than in healthy subjects. During fluvoxamine therapy, CCK-8 values increased, reaching normal levels by month 4 of treatment. No such increase occurred during amineptine therapy. Baseline beta-EP values were normal in the bulimic patients but had declined by month 4 of fluvoxamine therapy.

    Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; beta-Endorphin; Bulimia; Cognitive Behavioral Therapy; Combined Modality Therapy; Dibenzocycloheptenes; Female; Fluvoxamine; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Sincalide; T-Lymphocytes; Treatment Outcome

1995
Cholecystokinin octapeptide and bulimia nervosa.
    The American journal of psychiatry, 1994, Volume: 151, Issue:7

    Topics: Bulimia; Female; Humans; Male; Research Design; Sex Factors; Sincalide; Statistics as Topic

1994
CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects.
    The American journal of psychiatry, 1993, Volume: 150, Issue:7

    Cholecystokinin octapeptide (CCK-8) appears to modulate appetitive behavior, and in rodents, anxiety-related behavior. The authors studied CCK-8 in patients with bulimia nervosa. CSF concentrations of CCK-8 were measured in 11 drug-free female patients with DSM-III-R-defined bulimia nervosa and in 16 normal subjects. The bulimic patients had significantly lower levels of CCK-8 than the comparison subjects. CCK-8 concentrations were inversely correlated with scores on the anger-hostility, anxiety, and interpersonal sensitivity subscales of the SCL-90-R. They were not significantly correlated with age, percentage of standardized average body weight, or mean weekly frequency of binge eating or vomiting. The results indicate that central CCK-8 abnormalities may play a role in the pathophysiology of bulimia nervosa.

    Topics: Adult; Age Factors; Body Weight; Bulimia; Eating; Female; Humans; Male; Psychiatric Status Rating Scales; Serotonin; Sex Factors; Sincalide

1993